ES2290292T3 - Uso de acetil l-carnitina para la preparacion de un medicamento para la terapia preventiva contra el dolor posquirurgico. - Google Patents

Uso de acetil l-carnitina para la preparacion de un medicamento para la terapia preventiva contra el dolor posquirurgico. Download PDF

Info

Publication number
ES2290292T3
ES2290292T3 ES02728055T ES02728055T ES2290292T3 ES 2290292 T3 ES2290292 T3 ES 2290292T3 ES 02728055 T ES02728055 T ES 02728055T ES 02728055 T ES02728055 T ES 02728055T ES 2290292 T3 ES2290292 T3 ES 2290292T3
Authority
ES
Spain
Prior art keywords
carnitine
acetyl
acid
pain
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02728055T
Other languages
English (en)
Spanish (es)
Inventor
Menotti c/o Sigma-Tau Industrie CALVANI
Luigi c/o Sigma-Tau Industrie Farmac. MOSCONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2290292T3 publication Critical patent/ES2290292T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES02728055T 2001-05-29 2002-05-24 Uso de acetil l-carnitina para la preparacion de un medicamento para la terapia preventiva contra el dolor posquirurgico. Expired - Lifetime ES2290292T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000293A ITRM20010293A1 (it) 2001-05-29 2001-05-29 Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
ITRM01A0293 2001-05-29

Publications (1)

Publication Number Publication Date
ES2290292T3 true ES2290292T3 (es) 2008-02-16

Family

ID=11455557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02728055T Expired - Lifetime ES2290292T3 (es) 2001-05-29 2002-05-24 Uso de acetil l-carnitina para la preparacion de un medicamento para la terapia preventiva contra el dolor posquirurgico.

Country Status (18)

Country Link
US (2) US20040152781A1 (enExample)
EP (1) EP1399141B1 (enExample)
JP (1) JP4287660B2 (enExample)
KR (1) KR100873748B1 (enExample)
AT (1) ATE374021T1 (enExample)
CA (1) CA2448242C (enExample)
CY (1) CY1107037T1 (enExample)
CZ (1) CZ20033220A3 (enExample)
DE (1) DE60222662T2 (enExample)
DK (1) DK1399141T3 (enExample)
ES (1) ES2290292T3 (enExample)
HU (1) HUP0401294A3 (enExample)
IT (1) ITRM20010293A1 (enExample)
MX (1) MXPA03010919A (enExample)
PL (1) PL367616A1 (enExample)
PT (1) PT1399141E (enExample)
SK (1) SK287559B6 (enExample)
WO (1) WO2002096409A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040606A1 (it) 2004-12-13 2005-03-13 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per il trattamento della sindrome fibromialgica.
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
IT202200022437A1 (it) 2022-11-02 2024-05-02 Chiesi Italia S P A Composizione farmaceutica comprendente l-acetilcarnitina e beta-cariofillene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3463261D1 (en) * 1983-12-28 1987-05-27 Sigma Tau Ind Farmaceuti Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Also Published As

Publication number Publication date
US20090062388A1 (en) 2009-03-05
KR100873748B1 (ko) 2008-12-12
JP2004532865A (ja) 2004-10-28
CA2448242C (en) 2011-01-11
SK287559B6 (sk) 2011-02-04
JP4287660B2 (ja) 2009-07-01
WO2002096409A1 (en) 2002-12-05
SK15842003A3 (sk) 2004-06-08
KR20040003030A (ko) 2004-01-07
CY1107037T1 (el) 2012-09-26
EP1399141B1 (en) 2007-09-26
ATE374021T1 (de) 2007-10-15
ITRM20010293A0 (it) 2001-05-29
CA2448242A1 (en) 2002-12-05
PT1399141E (pt) 2007-11-16
US20040152781A1 (en) 2004-08-05
ITRM20010293A1 (it) 2002-11-29
HUP0401294A3 (en) 2008-04-28
DK1399141T3 (da) 2008-01-02
DE60222662D1 (de) 2007-11-08
CZ20033220A3 (en) 2004-06-16
EP1399141A1 (en) 2004-03-24
PL367616A1 (en) 2005-03-07
MXPA03010919A (es) 2004-02-27
DE60222662T2 (de) 2008-06-26
HUP0401294A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
EP1112067B1 (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
EP1219624B1 (en) Remedies for neuropathic pain and model animals of neuropathic pain
Tan et al. Patient-controlled epidural analgesia with morphine or morphine plus ketamine for post-operative pain relief
KR101864559B1 (ko) 정맥 내 투여용 이부프로펜의 투여
US20090062388A1 (en) Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain
Ali et al. Effect of intraperitoneal magnesium sulfate on hemodynamic changes and its analgesic and antiemetic effect in laparoscopic cholecystectomy
RU2322977C1 (ru) Синтетическое анальгетическое средство и способ лечения на основе этого средства
EP2830605A1 (en) A combination medicament comprising phenylephrine and paracetamol
US20210212967A1 (en) Treatment of Irritable Bowel Syndrome
Rawal Spinal opioids
ES2293245T3 (es) Combinacion farmaceutica para el tratamiento de la espasticidad y/o del dolor.
Johnson Treatment of acute pain in cats
EP1244498B1 (en) Combination of trimebutine with an opioid analgesic
Elenain et al. Comparative clinical study between dexmedetomidine and fentanyl as adjuvants to bupivacaine in ultrasound-guided supraclavicular brachial plexus block for upper limb surgeries: a randomized study
Williams Current views of the pharmacological management of pain
JPH1129476A (ja) 麻薬依存抑制剤
AU2006278933A1 (en) Therapeutic combination comprising a NMDA receptors blocker and a narcotic analgesic substance
PL207015B1 (pl) Zastosowanie pochodnych 2-indanyloaminowych do wytwarzania leku do leczenia bólu
Jung et al. Combination of nefopam and remifentanil is more effective to reduce rocuronium-induced withdrawal response compared with remifentanil alone: a prospective, double-blinded, randomized control study
Jensen et al. Accurate diagnosis and drug selection in patients with chronic pain
De Castro et al. Side effects
HK1168000A (en) Administration of intravenous ibuprofen